267890-56-2Relevant academic research and scientific papers
MONO AND COMBINATION THERAPY OF M1/M4 AGONIST (SABCOMELINE) FOR TREATMENT OF NEGATIVE SYMPTOMS OF SCHIZOPHRENIA
-
Page/Page column 35, (2008/06/13)
The invention relates to the use of a functional muscarinic M1/M4 receptor agonist or a pharmaceutically acceptable salt thereof for the treatment of negative symptoms of schizophrenia. It also relates to adjunctive and simultaneous combination therapies for the treatment of negative symptoms of schizophrenia in which the functional muscarinic M1/M4 receptor agonist or a pharmaceutically acceptable salt thereof, in particular sabcomeline or a pharmaceutically acceptable salt thereof and at least one neuroprotective agent, neuroleptic and/or atypical antipsychotic agent are administered adjunctively or simultaneously. The invention also provides methods of treatment of the negative symptoms of schizophrenia utilising such therapies and such adjunctive or simultaneous therapeutic combination therapies, therapeutic combinations for use therein and pharmaceutical compositions comprising them.
MONO AND COMBINATION THERAPY WITH A M1/M4 MUSCARINIC AGONIST (SABCOMELINE) FOR TREATMENT OF COGNITIVE DISORDERS IN SCHIZOPHRENIA
-
Page/Page column 30, (2008/06/13)
The invention relates to the use of a functional muscarinic M1/M4 receptor agonist such as the functional muscarinic M1/M4 receptor agonist or a pharmaceutically acceptable salt thereof, in particular sabcomeline or a pharmaceutically acceptable salt thereof in for the treatment of cognitive impairment in schizophrenia and to combination therapies for the treatment of cognitive impairment in schizophrenia which the functional muscarinic M1/M4 receptor agonist or a pharmaceutically acceptable salt thereof, in particular sabcomeline or a pharmaceutically acceptable salt thereof and at least one other neuroprotective agent and/or neuroleptic and/or atypical antipsyhcotic agent are administered adjunctively or simultaneously. The invention provides methods of treatment of cognitive impairment in schizophrenia utilising such therapies and such adjunctive or simultaneous therapeutic combination therapies, therapeutic combinations for use therein and pharmaceutical compositions comprising them.
MONO AND COMBINATION THERAPY WITH M1/M4 MUSCARINIC AGONIST (SABCOMELINE) FOR TREATMENT OF PRODROMAL SYNDROME
-
Page/Page column 12, (2010/11/29)
The invention relates to the use of a functional muscarinic M1/M4 agonist or a pharmaceutically acceptable salt thereof to treat prodromal syndrome and in the manufacture of a medicament for the treatment of prodromal syndrome, and to a method of treatment of prodromal syndrome using a functional muscarinic M1/M4 agonist or a pharmaceutically acceptable salt thereof. It also relates to the use of a pharmaceutical composition comprising a functional muscarinic M1/M4 agonist or a pharmaceutically acceptable salt thereof, and at least one cholinergic agent and/or at least one non-cholinergic agent for the treatment of prodromal syndrome, and to a method of treatment of prodromal syndrome by administration of a such a pharmaceutical composition.
